Called Air by Propeller, it provides local asthma conditions to anyone in the US who would like to share this insight with their audiences.
The two companies will undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK's ELLIPTA Inhaler.
Using Wing, users are able to detect early declines in lung function and take action to prevent asthma attacks, even before any symptoms were noticed.
The study demonstrated effectiveness of the Propeller Health Asthma Management Platform to better manage chronic respiratory disease.
The fully-integrated device delivers accurate doses to asthma and COPD patients, whilst providing on-screen instructions and feedback to the patient.
The funds will be used to expedite an FDA approval for the adult diagnostic test, expand into in-clinic use, and enter European and Asian markets.
Together with Allergy & Asthma Network, the company will develop a series of services for people with asthma and allergies.
The device's built-in sensors track the date and time when medication is actuated, which is then stored in onboard memory, and shared via Bluetooth.
Patients will have the opportunity to enroll in a new program to determine how Propeller's hi-tech tool can impact adherence rates and patient engagement.
Researchers plan to recruit 675 adults to investigate the safety and efficacy of three different treatment regimens for mild asthma.